[go: up one dir, main page]

WO2017003153A1 - Méthode de production de cellules tueuses naturelles à partir de monocytes de sang de cordon ombilical, ou de cellules dérivées de ces derniers - Google Patents

Méthode de production de cellules tueuses naturelles à partir de monocytes de sang de cordon ombilical, ou de cellules dérivées de ces derniers Download PDF

Info

Publication number
WO2017003153A1
WO2017003153A1 PCT/KR2016/006899 KR2016006899W WO2017003153A1 WO 2017003153 A1 WO2017003153 A1 WO 2017003153A1 KR 2016006899 W KR2016006899 W KR 2016006899W WO 2017003153 A1 WO2017003153 A1 WO 2017003153A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
natural killer
cord blood
cell
hut78
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2016/006899
Other languages
English (en)
Korean (ko)
Inventor
정혜진
민보경
최하나
황유경
김은지
김효진
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mogam Institute for Biomedical Research
GC Cell Corp
Original Assignee
Mogam Institute for Biomedical Research
Green Cross Lab Cell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Institute for Biomedical Research, Green Cross Lab Cell Corp filed Critical Mogam Institute for Biomedical Research
Publication of WO2017003153A1 publication Critical patent/WO2017003153A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens

Definitions

  • Figure 4a is a graph showing the proliferation rate of natural killer cells according to the number of re-stimulation when incubating the enriched natural killer cells with HuT78 support cells as seed cells.
  • the re-stimulation may be repeated one or more times at intervals of 5 to 12 days starting on day 0 of the culture, preferably may be repeated one or more times at intervals of 7 days, but is not limited thereto.
  • cells may be obtained 5 days after the last stimulus, preferably 14 days, but this is also not limiting.
  • Tube 5 anti-human CD3-FITC, anti-human NKp44-PE (BD Pharmingen, 558563), anti-human CD56-PE-Cy5
  • Natural killer cells cultured with various supporting cells were reacted with various tumor cell lines to measure direct cell killing ability.
  • Inhibitory KIR analysis showed that the ratio of CD158a (-) CD158b (-) CD158e (-) cells (KIR (-) cells) of natural killer cells obtained from cells derived from cord blood mononuclear cells was higher than that of PBMC (Fig. 8b).

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une méthode pour faire proliférer et produire des cellules tueuses naturelles qui permet une production en masse de cellules tueuses naturelles à forte activité tueuse et pouvant être d'application clinique, à partir d'une petite quantité de monocytes de sang de cordon ombilical ou de cellules dérivées de ces derniers, en co-cultivant des monocytes de sang de cordon ombilical ou des cellules dérivées de ces derniers avec des cellules TCD4(+) et en les faisant proliférer, et, de ce fait, la méthode peut être utilisée dans la commercialisation d'agents thérapeutiques cellulaires dérivés de sang de cordon ombilical.
PCT/KR2016/006899 2015-06-29 2016-06-28 Méthode de production de cellules tueuses naturelles à partir de monocytes de sang de cordon ombilical, ou de cellules dérivées de ces derniers Ceased WO2017003153A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0092055 2015-06-29
KR20150092055 2015-06-29

Publications (1)

Publication Number Publication Date
WO2017003153A1 true WO2017003153A1 (fr) 2017-01-05

Family

ID=57608675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/006899 Ceased WO2017003153A1 (fr) 2015-06-29 2016-06-28 Méthode de production de cellules tueuses naturelles à partir de monocytes de sang de cordon ombilical, ou de cellules dérivées de ces derniers

Country Status (1)

Country Link
WO (1) WO2017003153A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107475196A (zh) * 2017-10-09 2017-12-15 天津长和生物技术有限公司 自然杀伤细胞培养基质及自然杀伤细胞的扩增培养方法
CN113403273A (zh) * 2021-06-25 2021-09-17 江苏蒙彼利生物科技有限公司 一种扩增脐带血来源的nk细胞的培养方法
CN114058584A (zh) * 2022-01-07 2022-02-18 山东省齐鲁干细胞工程有限公司 一种临床用自然杀伤细胞的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100045704A (ko) * 2008-10-24 2010-05-04 주식회사 메디셀 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법
KR20120100207A (ko) * 2011-03-03 2012-09-12 한국생명공학연구원 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법
JP2013071915A (ja) * 2011-09-28 2013-04-22 Biotherapy Institute Of Japan Ｎｋ細胞強化型血液製剤の製造方法
JP2013143970A (ja) * 2013-05-01 2013-07-25 Cellex:Kk Ｎｋ細胞活性化方法、これを用いたｎｋ細胞増殖方法及び細胞製造方法並びにｎｋ細胞を含む単核球
KR20140123503A (ko) * 2011-12-22 2014-10-22 재단법인 목암생명공학연구소 자연살해세포의 제조방법, 이러한 방법에 의해 제조된 자연살해세포 및 이를 포함하는 종양 및 감염성 질환 치료용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100045704A (ko) * 2008-10-24 2010-05-04 주식회사 메디셀 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법
KR20120100207A (ko) * 2011-03-03 2012-09-12 한국생명공학연구원 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법
JP2013071915A (ja) * 2011-09-28 2013-04-22 Biotherapy Institute Of Japan Ｎｋ細胞強化型血液製剤の製造方法
KR20140123503A (ko) * 2011-12-22 2014-10-22 재단법인 목암생명공학연구소 자연살해세포의 제조방법, 이러한 방법에 의해 제조된 자연살해세포 및 이를 포함하는 종양 및 감염성 질환 치료용 조성물
JP2013143970A (ja) * 2013-05-01 2013-07-25 Cellex:Kk Ｎｋ細胞活性化方法、これを用いたｎｋ細胞増殖方法及び細胞製造方法並びにｎｋ細胞を含む単核球

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107475196A (zh) * 2017-10-09 2017-12-15 天津长和生物技术有限公司 自然杀伤细胞培养基质及自然杀伤细胞的扩增培养方法
CN113403273A (zh) * 2021-06-25 2021-09-17 江苏蒙彼利生物科技有限公司 一种扩增脐带血来源的nk细胞的培养方法
CN113403273B (zh) * 2021-06-25 2023-04-25 江苏蒙彼利生物科技有限公司 一种扩增脐带血来源的nk细胞的培养方法
CN114058584A (zh) * 2022-01-07 2022-02-18 山东省齐鲁干细胞工程有限公司 一种临床用自然杀伤细胞的制备方法

Similar Documents

Publication Publication Date Title
WO2016085248A1 (fr) Procédé de culture de cellules tueuses naturelles à l'aide de lymphocytes t
WO2016209021A1 (fr) Méthode pour faire proliférer des cellules tueuses naturelles et composition pour faire proliférer des cellules tueuses naturelles
KR102575976B1 (ko) 자연살해 세포의 증식방법
AU2025202866A1 (en) Methods for the production of TCR gamma delta+ T cells
KR101866827B1 (ko) 방사선 조사된 말초혈액단핵구를 이용한 고효율 자연살상세포의 제조방법 및 이를 이용한 항암 면역 세포치료제 조성물
WO2018217064A2 (fr) Procédé de culture de cellules tueuses naturelles au moyen d'un lymphocyte t transformé
WO2019182422A1 (fr) Nouvelle lignée de cellules tueuses naturelles génétiquement modifiées et son utilisation
WO2021054789A1 (fr) Lignée de cellules nk génétiquement modifiée transduite avec un gène codant pour un nouveau récepteur d'antigène chimère et son utilisation
WO2020101361A1 (fr) Procédé de culture de cellules tueuses naturelles dérivées de sang de cordon ombilical au moyen de lymphocytes t transformés
KR101867942B1 (ko) 바이러스 항원 특이적인 t 세포의 유도 및 증식 방법
KR20200135514A (ko) 케모카인 리셉터와 세포 접착 분자를 발현하는 cd3 음성 세포의 집단, 및 그 이용 그리고 그 제조 방법
WO2019182392A1 (fr) Procédé de production de cellules tueuses naturelles
WO2017003153A1 (fr) Méthode de production de cellules tueuses naturelles à partir de monocytes de sang de cordon ombilical, ou de cellules dérivées de ces derniers
Michen et al. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self
Zhou et al. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia
van Hauten et al. Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity
Rolink et al. The potential involvement of Notch signaling in NK cell development
WO2013168978A1 (fr) Méthode d'induction et de prolifération de cellules tueuses naturelles dérivées de cellules mononucléaires du sang périphérique
TW202134427A (zh) 含有nk細胞之細胞集團之製造方法
WO2019231243A1 (fr) Cellule nourricière exprimant ox40l et procédé de culture de cellules tueuses naturelles l'utilisant
KR20180026726A (ko) Ｔｃｒ감마 델타 양성 ｔ 세포의 생산 방법
WO2022080894A1 (fr) Cellule tueuse naturelle ayant une expression régulée d'un gène ayant une utilité oncologique, et son utilisation
Mou et al. 2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway
WO2021251707A1 (fr) Lignée cellulaire génétiquement modifiée pour l'activation et l'amplification de cellules nk et utilisation associée
WO2016117960A1 (fr) Cellules souches mésenchymateuses surexprimées par grim19 efficaces dans le traitement d'une maladie immunitaire, et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16818186

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16818186

Country of ref document: EP

Kind code of ref document: A1